JP2013524792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013524792A5 JP2013524792A5 JP2013505367A JP2013505367A JP2013524792A5 JP 2013524792 A5 JP2013524792 A5 JP 2013524792A5 JP 2013505367 A JP2013505367 A JP 2013505367A JP 2013505367 A JP2013505367 A JP 2013505367A JP 2013524792 A5 JP2013524792 A5 JP 2013524792A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- absent
- nucleotides
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 51
- 150000007523 nucleic acids Chemical class 0.000 claims 51
- 102000039446 nucleic acids Human genes 0.000 claims 51
- 239000002773 nucleotide Substances 0.000 claims 38
- 125000003729 nucleotide group Chemical group 0.000 claims 38
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims 15
- 239000000523 sample Substances 0.000 claims 14
- 239000005557 antagonist Substances 0.000 claims 6
- 238000001514 detection method Methods 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 4
- 108091028664 Ribonucleotide Proteins 0.000 claims 3
- 239000002336 ribonucleotide Substances 0.000 claims 3
- 125000002652 ribonucleotide group Chemical group 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000005547 deoxyribonucleotide Substances 0.000 claims 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10004253 | 2010-04-21 | ||
| EP10004253.0 | 2010-04-21 | ||
| EP11000117.9 | 2011-01-10 | ||
| EP11000117 | 2011-01-10 | ||
| PCT/EP2011/002068 WO2011131371A1 (en) | 2010-04-21 | 2011-04-21 | Lipid binding nucleic acids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013524792A JP2013524792A (ja) | 2013-06-20 |
| JP2013524792A5 true JP2013524792A5 (enExample) | 2014-06-05 |
| JP5941904B2 JP5941904B2 (ja) | 2016-06-29 |
Family
ID=44201395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505367A Expired - Fee Related JP5941904B2 (ja) | 2010-04-21 | 2011-04-21 | 脂質に結合する核酸 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8871920B2 (enExample) |
| EP (1) | EP2561079A1 (enExample) |
| JP (1) | JP5941904B2 (enExample) |
| CN (1) | CN102906265B (enExample) |
| WO (1) | WO2011131371A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2824073A1 (en) | 2011-01-10 | 2012-07-19 | Noxxon Pharma Ag | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
| PL2802660T3 (pl) | 2012-01-10 | 2020-07-27 | Aptarion Biotech Ag | Nowe kwasy nukleinowe wiążące c5a |
| MX2014008456A (es) | 2012-01-10 | 2014-11-25 | Noxxon Pharma Ag | Acidos nucleicos que enlazan especificamente a cgrp. |
| CN109475756A (zh) * | 2016-02-17 | 2019-03-15 | 儿童医疗中心有限公司 | Ffa1(gpr40)作为神经血管生成疾病或病症的治疗标靶 |
| EP3264092A1 (en) | 2016-07-01 | 2018-01-03 | Centogene AG | Use of lyso-gb1 as druggable target |
| US11172873B2 (en) | 2018-05-17 | 2021-11-16 | The Procter & Gamble Company | Systems and methods for hair analysis |
| MX2020012225A (es) | 2018-05-17 | 2021-01-29 | Procter & Gamble | Sistemas y metodos para el analisis de la cobertura del cabello. |
| WO2020005325A1 (en) * | 2018-06-29 | 2020-01-02 | The Procter & Gamble Company | Aptamers for hair care applications |
| US11384357B2 (en) | 2018-06-29 | 2022-07-12 | The Procter And Gamble Company | Aptamers for personal care applications |
| CN109402127B (zh) * | 2018-09-29 | 2021-12-10 | 复旦大学附属眼耳鼻喉科医院 | 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用 |
| WO2020214784A1 (en) | 2019-04-16 | 2020-10-22 | The Procter & Gamble Company | Aptamers for odor control applications |
| MX2021015418A (es) * | 2019-07-17 | 2022-04-12 | Noxopharm Ltd | Terapia inmunooncologica. |
| US12039732B2 (en) | 2021-04-14 | 2024-07-16 | The Procter & Gamble Company | Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US6225063B1 (en) * | 1998-05-22 | 2001-05-01 | University Technology Corporation | RNA channels in biological membranes |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| ATE469164T1 (de) | 2001-10-26 | 2010-06-15 | Noxxon Pharma Ag | Modifizierte l-nukleinsäure |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| ATE441706T1 (de) | 2002-02-20 | 2009-09-15 | Gen Hospital Corp | Konjugate mit biologisch abbaubarem polymer und verwendung dafür |
| RU2394041C2 (ru) | 2003-04-13 | 2010-07-10 | Энзон Фармасьютикалз, Инк. | Полимерные олигонуклеотидные пролекарства |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| EP1713509A2 (de) | 2004-02-09 | 2006-10-25 | Noxxon Pharma AG | Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden |
| CA2940803A1 (en) | 2004-03-23 | 2005-10-27 | Ascendis Pharma Gmbh | Prodrug linker |
| WO2006052790A2 (en) | 2004-11-05 | 2006-05-18 | The Children's Hospital Of Philadelphia | Biodegradable linkers for molecular therapies |
| CN101217967B (zh) | 2005-05-04 | 2014-09-10 | 诺松制药股份公司 | 镜像异构体的新用途 |
| US20090074720A1 (en) * | 2005-10-28 | 2009-03-19 | Sabbadini Roger A | Methods for decreasing immune response and treating immune conditions |
| US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
| AU2007296054B2 (en) | 2006-09-15 | 2013-03-28 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| US20100062436A1 (en) | 2006-10-31 | 2010-03-11 | Noxxon Pharma Ag | Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule |
-
2011
- 2011-04-21 EP EP11716838A patent/EP2561079A1/en not_active Withdrawn
- 2011-04-21 US US13/642,555 patent/US8871920B2/en not_active Expired - Fee Related
- 2011-04-21 JP JP2013505367A patent/JP5941904B2/ja not_active Expired - Fee Related
- 2011-04-21 WO PCT/EP2011/002068 patent/WO2011131371A1/en not_active Ceased
- 2011-04-21 CN CN201180024560.5A patent/CN102906265B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013524792A5 (enExample) | ||
| JP2023153949A (ja) | ヒトｅｚｈ２の阻害剤、およびその使用方法 | |
| Glahn et al. | Rediscovering the value of families for psychiatric genetics research | |
| Ripke et al. | Genome-wide association analysis identifies 13 new risk loci for schizophrenia | |
| JP6307675B2 (ja) | 標的タンパク質に結合する核酸断片 | |
| JP2014533098A5 (enExample) | ||
| JP2009543567A5 (enExample) | ||
| JP2013540423A5 (enExample) | ||
| ES2629183T3 (es) | Aptámeros para diagnóstico de Clostridium difficile | |
| RU2008136907A (ru) | Нуклеиновые кислоты, связывающиеся с мср-1 | |
| CN101892311A (zh) | 高血压易感基因的单核苷酸多态性位点rs7550536的检测方法及检测试剂盒 | |
| JP2015506174A5 (enExample) | ||
| JP2009526532A5 (enExample) | ||
| RU2014132706A (ru) | Нуклеиновые кислоты, специфически связывающие cgrp | |
| Donnelly et al. | Genome-wide association analysis identifies 13 new risk loci for schizophrenia | |
| JP2018504909A5 (enExample) | ||
| Zhou et al. | Fast and sensitive multivalent spatial pattern-recognition for circular RNA detection | |
| Libonati et al. | Genetics screening in an Italian cohort of patients with amyotrophic lateral sclerosis: the importance of early testing and its implication | |
| Chen et al. | Functional characterization and clinical implication of a novel epidemic carbapenem-resistant Acinetobacter baumannii genetic marker | |
| WO2018159750A1 (ja) | オピオイド薬の治療有効性を予測するためのｍｉｃｒｏＲＮＡバイオマーカー | |
| CN101892297B (zh) | 高血压易感基因单核苷酸多态性位点的检测方法及其试剂盒 | |
| Sacharczuk et al. | A polymorphism in exon 2 of the δ-opioid receptor affects nociception in response to specific agonists and antagonists in mice selectively bred for high and low analgesia | |
| WO2018170289A1 (en) | Methods of determining differential aging and genetic modifiers of genes correlated with a genotype of interest | |
| Zhang et al. | Genotypic and phenotypic characteristics of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy from China | |
| CN101892298B (zh) | 高血压易感基因单核苷酸多态性位点rs2236055的检测方法及其试剂盒 |